10.28.13
Evotec AG has achieved its first milestones in its multi-target drug discovery collaboration with UCB in the field of immunology. The milestones included the progression of certain projects into hit-to-lead and lead optimization. Financial terms were not disclosed.
Under the collaboration, entered in October 2011, Evotec receives research payments and preclinical, clinical, and sales milestones, as well as royalties on product sales.
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are delighted that the project teams at UCB and Evotec have met these important milestones in the collaboration. The progress in this collaboration is a testament to the way scientists from both companies have worked together in a true partnership."
Dr. Neil Weir, senior vice president of Discovery at UCB, said, "The collaboration with Evotec complements our internal research efforts and enhances our scientific network. Hitting these milestones is great news and as we continue to work together, we hope that the results will enhance the pace of the discovery process, the quality of compounds selected for further development and ultimately improve patient outcomes."
Under the collaboration, entered in October 2011, Evotec receives research payments and preclinical, clinical, and sales milestones, as well as royalties on product sales.
Dr. Mario Polywka, chief operating officer of Evotec, said, "We are delighted that the project teams at UCB and Evotec have met these important milestones in the collaboration. The progress in this collaboration is a testament to the way scientists from both companies have worked together in a true partnership."
Dr. Neil Weir, senior vice president of Discovery at UCB, said, "The collaboration with Evotec complements our internal research efforts and enhances our scientific network. Hitting these milestones is great news and as we continue to work together, we hope that the results will enhance the pace of the discovery process, the quality of compounds selected for further development and ultimately improve patient outcomes."